SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : JB Chemicals & Pharmaceuticals Ltd

BSE: 506943 NSE: JBCHEPHARM ISIN: INE572A01036
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does JB Chemicals & Pharmaceuticals Ltd belong to?
JB Chemicals & Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is JB Chemicals & Pharmaceuticals Ltd a good quality company?
JB Chemicals & Pharmaceuticals Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is JB Chemicals & Pharmaceuticals Ltd undervalued or overvalued?
JB Chemicals & Pharmaceuticals Ltd appears Overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is JB Chemicals & Pharmaceuticals Ltd a good buy now?
JB Chemicals & Pharmaceuticals Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of JB Chemicals & Pharmaceuticals Ltd?
JB Chemicals & Pharmaceuticals Ltd revenue growth is 12.9% for FY-2025 , which is below its 5 year CAGR of 17.8% , indicating slower growth.
Q.2 Gross Profit margin of JB Chemicals & Pharmaceuticals Ltd?
JB Chemicals & Pharmaceuticals Ltd Gross profit margin which is the profit after deduction of direct costs, is 27% for FY-2025 , which is above its 5 year median of 25.6% , indicating increasing margins.
Q.3 Operating Profit Margin of JB Chemicals & Pharmaceuticals Ltd?
JB Chemicals & Pharmaceuticals Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 27.27% for FY-2025 , which is above its 5 year median of 26.6% indicating increasing margins.
Q.4 Net Profit Margin of JB Chemicals & Pharmaceuticals Ltd?
JB Chemicals & Pharmaceuticals Ltd Net Profit Margin is 17.53% for FY-2025 , is above with its 5 year median of 16.49%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 27 25.6
Operating Profit Margin 27.27 26.6
Net Profit Margin 17.53 16.49
Q.5 Return on Asset of JB Chemicals & Pharmaceuticals Ltd?
JB Chemicals & Pharmaceuticals Ltd Return on Asset is 13.69%, which is above its 5 year historical median of 13.04%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of JB Chemicals & Pharmaceuticals Ltd?
JB Chemicals & Pharmaceuticals Ltd Return on equity is 21.91% for FY-2025 , which is above its historical median of 21.45%, indicating the business is making better use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of JB Chemicals & Pharmaceuticals Ltd?
JB Chemicals & Pharmaceuticals Ltd Return on capital employed is 26.83% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 11.25%, indicating value creation.
Q.8 Cash conversion cycle of JB Chemicals & Pharmaceuticals Ltd?
JB Chemicals & Pharmaceuticals Ltd Cash conversion cycle is 61 days, below its historical median of 73 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.81 0.81
ROE 21.91 21.45
ROCE 26.83 25.13
Cash Conversion Cycle 61 days 73 days
Q.9 Debt to Equity ratio of JB Chemicals & Pharmaceuticals Ltd?
JB Chemicals & Pharmaceuticals Ltd Debt-to-Equity ratio is 0.00 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of JB Chemicals & Pharmaceuticals Ltd?
JB Chemicals & Pharmaceuticals Ltd Debt to cash flow from operations is 0 , which is at a healthy level, indicating the business is able to service its debt comfortably.

Ownership & governance

Q.1 Promoter shareholding and pledge status of JB Chemicals & Pharmaceuticals Ltd?
Promoters hold 47.55% of the JB Chemicals & Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of JB Chemicals & Pharmaceuticals Ltd vs industry peers?
JB Chemicals & Pharmaceuticals Ltd revenue CAGR is 17.81% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 3,722.9 137.1
Gross Profit 1,005.2 15.1
Operating Profit 1,015 16
Net Profit 653 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.81 0.8
ROE 21.91 8.91
ROCE 26.83 11.59
Cash Conversion Cycle (days) 60.81 76

Valuation & price assessment

Q.1 Stock return of JB Chemicals & Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 32% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 32% 26.5% 22.7% 26.9%
Q.3 Valuation ratios of JB Chemicals & Pharmaceuticals Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 44.12 18.56 40.28
Price to Book 8.22 3.92 2.77
Price to Sales 8.11 3.57 2.65
EV to EBITDA 27.86 12.48 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Pfizer
6. Wockhardt
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Acutaas Chemicals
10. Piramal Pharma
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×